| Long name: |
Cy5, 5 Conjugated, AGER Polyclonal Antibody |
| Category: |
Conjugated Primary Antibodies |
| Conjugation: |
Cy5, 5, 5, Cy5 |
| Host Organism: |
Rabbit (Oryctolagus cuniculus) |
| Target Antigen: |
AGER |
| Specificity: |
This is a highly specific antibody against AGER |
| Modification: |
Unmodified |
| Modification site: |
None |
| Clonality: |
Polyclonal |
| Clone: |
Polyclonal antibody |
| Concentration: |
1ug per 1ul |
| Immunogen_range: |
30-80/404 |
| Subcellular location: |
Extracellular |
| Source: |
KLH conjugated synthetic peptide derived from human AGER |
| Gene ID number: |
177 |
| Swiss Prot: |
Q15109 |
| Tested applications: |
IF(IHC-P) |
| Recommended dilutions: |
IF(IHC-P)(1:50-200) |
| Crossreactivity: |
Mouse, Rat, Human |
| Crossreactive species details: |
not every possible cross-reactivity is known, Due to limited amount of testing and knowledge |
| Antigen background: |
ABPP-initiated RAGE signaling, AGE/RAGE signaling plays an important role in regulating the production/expression of TNF-alpha, Acts as a mediator of both acute and chronic vascular inflammation in conditions such as atherosclerosis and in particular as a complication of diabetes, Can also bind oligonucleotides, Contributes to the translocation of amyloid-beta peptide (ABPP) across the cell membrane from the extracellular to the intracellular space in cortical neurons, Interaction with S100A12 on endothelium, Interaction with S100B after myocardial infarction may play a role in myocyte apoptosis by activating ERK1/2 and p53/TP53 signaling (By similarity), Receptor for amyloid beta peptide, These are nonenzymatically glycosylated proteins which accumulate in vascular tissue in aging and at an accelerated rate in diabetes, and endothelial dysfunction in type 2 diabetes, and lymphocytes triggers cellular activation, especially stimulation of p38 mitogen-activated protein kinase (MAPK), has the capacity to drive a transport system delivering ABPP as a complex with RAGE to the intraneuronal space, mononuclear phagocytes, oxidative stress, with generation of key proinflammatory mediators, Mediates interactions of advanced glycosylation end products (AGE) |
| Purification method: |
This antibody was purified via Protein A |
| Storage conditions: |
50% glycerol and 0, Store refrigerated at 2 to 8 degrees Celcius for up to 1 year, 09% sodium azide, Keep the antibody in an aqueous buffered solution containing 1% BSA |
| Excitation Emission: |
675nm/694nm |
| Synonyms: |
RAGE SCARJ1 |
| Properties: |
Cy5 antibodies are excited by the 650-nanometer wave of an argon laser and detected at a 670-nanometer captor, C, C for long term storage and for short term at + 5°, If you buy Antibodies supplied by Bioss Primary Conjugated Antibodies they should be stored frozen at - 24° |
| Conjugated: |
These antibodies are excite for emission at 678nm and detected at a 694 , nm wavelengths |
| Gene target: |
AGER Conjugated |
| Short name: |
Conjugated, AGER Antibody |
| Technique: |
antibodies against human proteins, antibodies for, antibody Conjugates, Antibody |
| Label: |
5, Cy5 |
| Alternative name: |
cyanine 5, 5 coupled, advanced glycosylation end product-specific receptor (Antibody to) |
| Alternative technique: |
antibodies |
| Alternative to gene target: |
AGER and IDBG-633065 and ENSBTAG00000014420 and 280986, AGER and IDBG-80463 and ENSG00000204305 and 177, Ager and IDBG-172144 and ENSMUSG00000015452 and 11596, Extracellular, RAGE, S100 protein binding, this GO :0004872 and receptor activity and molecular function this GO :0004888 and transmembrane signaling receptor activity and molecular function this GO :0005515 and protein binding and molecular function this GO :0005576 and extracellular region and cellular component this GO :0005886 and plasma membrane and cellular component this GO :0005887 and integral component of plasma membrane and cellular component this GO :0006954 and inflammatory response and biological process this GO :0007166 and cell surface receptor signaling pathway and biological process this GO :0009611 and response to wounding and biological process this GO :0016020 and membrane and cellular component this GO :0016021 and integral component of membrane and cellular component this GO :0031175 and neuron projection development and biological process this GO :0042802 and identical protein binding and molecular function this GO :0044548 and S100 protein binding and molecular function this GO :0045087 and innate immune response and biological process this GO :0050930 and induction of positive chemotaxis and biological process this GO :0051092 and positive regulation of NF-kappaB transcription factor activity and biological process, this GO :0004872 : receptor activity, this GO :0004872 : receptor activity and also this GO :0004888 : transmembrane signaling receptor activity and also this GO :0005515 : protein binding and also this GO :0042802 : identical protein binding and also this GO :0044548 : S100 protein binding, this GO :0004888 : transmembrane signaling receptor activity, this GO :0005515 : protein binding, this GO :0042802 : identical protein binding, this GO :0044548 : S100 protein binding, advanced glycosylation end product-specific receptor |
| Identity: |
320 |
| Gene: |
AGER |
More about : AGER |
| Long gene name: |
advanced glycosylation end-product specific receptor |
| Synonyms name: |
receptor for advanced glycation end-products |
| Locus: |
6p21, 32 |
| Discovery year: |
1994-10-17 |
| GenBank acession: |
M91211 |
| Entrez gene record: |
177 |
| Pubmed identfication: |
7713518 |
| RefSeq identity: |
NM_001136 |
| Classification: |
C2-set domain containing Immunoglobulin like domain containing Scavenger receptors |
| Havana BLAST/BLAT: |
OTTHUMG00000031120 |